免疫抑制剂与黑色素瘤及非黑色素瘤皮肤癌风险,第二部分:甲氨蝶呤、烷化剂、生物制剂及小分子抑制剂
本文综述甲氨蝶呤、烷化剂、生物制剂及小分子抑制剂相关黑色素瘤与非黑色素瘤皮肤癌风险证据,基于现有数据推荐对部分非移植患者接受已显示升高风险的免疫抑制方案时进行定期皮肤癌筛查,并提供高危患者谨慎使用建议及各类药物相对风险汇总。
要点
- 基于现有数据,推荐对接受已显示升高非黑色素瘤皮肤癌或黑色素瘤风险的免疫抑制方案的部分非移植患者进行定期皮肤癌筛查。
- 文中提供在高危患者中 conscientious 使用这些疗法的建议。
- 文末汇总各免疫抑制剂类别的相对风险及相关推荐。
核心结论
- 基于现有数据,推荐对接受已显示升高非黑色素瘤皮肤癌或黑色素瘤风险的免疫抑制方案的部分非移植患者进行定期皮肤癌筛查。
研究设计与样本
- 本文为综述,回顾甲氨蝶呤、环磷酰胺、生物制剂细胞因子抑制剂(包括TNF-α和白细胞介素抑制剂)、共刺激阻断剂(如阿巴西普)、整合素抑制剂(如那他珠单抗)、靶向B细胞和T细胞抑制剂(包括CD20、CD52和BTK抑制剂)及JAK抑制剂相关黑色素瘤和非黑色素瘤皮肤癌风险证据。
主要发现
- 文中综述了甲氨蝶呤、环磷酰胺、生物制剂细胞因子抑制剂、共刺激阻断剂、整合素抑制剂、靶向B细胞和T细胞抑制剂及JAK抑制剂与黑色素瘤和非黑色素瘤皮肤癌风险的证据。
- 文末呈现各免疫抑制剂类别相关相对风险的综合汇总及相关推荐。
临床怎么用
- 作者推荐对接受已显示升高非黑色素瘤皮肤癌或黑色素瘤风险的免疫抑制方案的部分非移植患者进行定期皮肤癌筛查。
- 作者还提供在高危患者中 conscientious 使用这些疗法的建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In solid organ transplant recipients, skin cancer risk associated with posttransplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used posttransplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF (tumor necrosis factor)-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors such as natalizumab, targeted B-cell, and T-cell inhibitors including CD20 (cluster of differentiate 20), CD52, and BTK (Bruton's tyrosine kinase) inhibitors, and JAK (Janus kinase) inhibitors is reviewed. Based on the available data, we recommend regular skin cancer screening for select nontransplant patients receiving immunosuppressive regimens that are shown to raise the risk of NMSC or melanoma. We also offer suggestions for conscientious use of these therapies in high-risk patients. Finally, a comprehensive summary of the relative risk associated with each immunosuppressant class and associated recommendations is presented.
引用
- Kreher MA, Konda S, Noland MMB, et al. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2022. PMID: 36460256. doi:10.1016/j.jaad.2022.11.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。